ArticleMedicine2026
Bioactive compounds from marine algae targeting MMP-9: A computational approach to rheumatoid arthritis treatment.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune systemic inflammatory condition that significantly damages bone and cartilage, leading to severe joint deformities. Matrix metalloproteinase(s) (MMP-9) plays a significant role in both the pathogenesis and management of RA, and its status as a biomarker and a target for inhibition is important in understanding and treating the disease. This work aims to examine the interactions between the molecules of MMP-9 and bioactive compounds derived from marine algae using molecular docking and absorption, distribution, metabolism, excretion, and toxicity investigations. Docking results were assessed using Glide gscore, the top 5 compounds (6,6-Bieckol, Dieckol, Lophocladine B, Sargachromanol E, and Porphyran) docked against protein receptors were chosen. The selected compounds had binding affinities that varied from -8.523 to -6.327 kcal/mol, and the selected compounds also had undergone absorption, distribution, metabolism, excretion, and toxicity analysis. Density functional theory analysis was conducted against finalized compound, Lophocladine B, with HOMO-LUMO gaps of 4.235 and 5.275 eV, respectively, confirming electronic stability and binding-relevant reactive sites consistent with its predicted MMP-9 inhibition. It was discovered that only Lophocladine B met the selection criteria, so this compound was subjected to molecular dynamics simulations for stability analysis. Moreover, the docking studies were supported by redocking validation of the native inhibitor, heavy-atom root mean square deviation, benchmarking with a known inhibitor, and molecular dynamics simulations along with a replication run. The results of the study imply that these substances might ultimately be employed to treat rheumatoid arthritis. Although this study only included computer validations, in vitro investigations are needed to convert these potential inhibitors into medicinal products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.